Acrivon Therapeutics ACRV Income Statement (2021-2026)

NASDAQ ACRV
$2.20 -0.19 (-7.74%)
As of: Aug 20, 2026 · 3:59 PM EDT
1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating items
Research & Development (Quarter) 18.45M9.76M10.52M10.27M15.48M11.47M15.03M18.86M18.63M15.41M16.18M13.65M14.75M15.17M13.84M
Selling, General & Administrative (Quarter) 4.63M5.00M5.87M5.58M6.20M6.41M6.28M6.32M6.25M6.47M6.04M5.37M4.74M4.82M
Other Operating Expenses (Quarter) 2.67M4.27M7.21M5.92M9.57M-8.50M
Operating Expenses (Quarter) 2.67M4.27M7.21M5.92M9.57M9.95M14.39M15.52M16.14M21.05M17.67M21.44M25.14M24.95M21.66M22.65M19.69M20.12M19.90M18.67M
Operating Income (Quarter) -2.67M-4.27M-7.21M-5.92M-9.57M-9.95M-14.39M-15.52M-16.14M-21.05M-17.67M-21.44M-25.14M-24.95M-21.66M-22.65M-19.69M-20.12M-19.90M-18.67M
EBIT (Quarter) -2.67M-4.27M-7.21M-5.92M-9.57M-9.95M-14.39M-15.52M-16.14M-21.05M-17.67M-21.44M-25.14M-24.95M-21.66M-22.65M-19.69M-20.12M-19.90M-18.67M
Non-operating items
Other Non Operating Income (Quarter) -0.00M-0.02M-0.01M0.10M0.38M1.02M-0.17M-0.16M-0.10M0.11M-0.26M-0.06M0.00M-0.24M-0.01M-0.09M-0.05M-0.12M-0.13M-0.16M
Non Operating Income (Quarter) 0.23M-0.07M-0.01M0.10M0.38M1.02M1.64M1.61M1.67M2.12M1.18M2.69M2.70M2.12M1.98M1.64M1.45M1.13M0.99M0.86M
Net income details
EBT (Quarter) -2.67M-6.28M-7.21M-5.92M-15.93M-10.24M-35.11M-35.02M-28.28M-21.35M-27.10M-26.44M-33.69M-25.45M-25.61M-23.05M-20.18M-21.17M-22.51M-20.93M
Profit After Tax (Quarter) -2.44M-4.34M-7.22M-5.82M-9.20M-8.96M-12.76M-13.91M-14.47M-19.26M-16.49M-18.80M-22.44M-22.83M-19.70M-21.01M-18.23M-18.65M-19.04M-18.00M
Income from Non-Controlling Interests (Quarter) -2.44M-4.34M-7.22M-5.82M-0.13M0.04M0.10M-0.44M0.12M0.22M0.01M0.05M0.80M-0.34M-0.16M-0.18M0.01M-0.00M-0.11M-0.04M
Income from Continuing Operations (Quarter) -2.67M-6.28M-7.21M-5.92M-15.93M-10.24M-35.11M-35.02M-28.28M-21.35M-27.10M-26.44M-33.69M-25.45M-25.61M-23.05M-20.18M-21.17M-22.51M-20.93M
Consolidated Net Income (Quarter) -2.67M-6.28M-7.21M-5.92M-15.93M-10.24M-35.11M-35.02M-28.28M-21.35M-27.10M-26.44M-33.69M-25.45M-25.61M-23.05M-20.18M-21.17M-22.51M-20.93M
Income towards Parent Company (Quarter) -2.67M-6.28M-7.21M-5.92M-15.93M-10.24M-35.11M-35.02M-28.28M-21.35M-27.10M-26.44M-33.69M-25.45M-25.61M-23.05M-20.18M-21.17M-22.51M-20.93M
Net Income towards Common Stockholders (Quarter) -2.67M-6.28M-7.21M-5.92M-15.93M-10.24M-35.11M-35.02M-28.28M-21.35M-27.10M-26.44M-33.69M-25.45M-25.61M-23.05M-20.18M-21.17M-22.51M-20.93M
Additional items
EPS (Basic) (Quarter) -1.51-3.60-4.08-3.35-8.96-2.49-1.60-1.59-1.28-0.97-1.20-0.73-0.88-0.75-0.67-0.60-0.52-0.55-0.58-0.54
EPS (Diluted) (Quarter) -1.51-3.60-4.08-3.35-8.96-2.49-1.60-1.59-1.28-0.97-1.20-0.73-0.88-0.75-0.67-0.60-0.52-0.55-0.58-0.54
Shares Outstanding (Quarter) 1.77M1.74M1.77M1.77M1.78M4.12M21.92M21.97M22.08M22.08M22.59M36.13M38.11M33.79M38.35M38.46M38.56M38.51M38.72M38.72M
Shares Outstanding (Diluted) (Quarter) 1.77M1.74M1.77M1.77M1.78M4.12M21.92M21.97M22.08M22.08M22.59M36.13M38.11M33.79M38.35M38.46M38.56M38.51M38.72M38.72M
Shares Outstanding (Entity) (Quarter) 1.77M1.77M1.77M1.77M1.79M4.12M21.92M22.07M22.10M22.52M22.64M30.97M31.13M31.23M31.35M31.45M31.55M31.65M38.75M42.85M
EBITDA (Quarter) -2.67M-4.27M-7.21M-5.92M-9.57M-9.95M-14.39M-15.52M-16.14M-21.05M-17.67M-21.44M-25.14M-24.95M-21.66M-22.65M-19.69M-20.12M-19.90M
Interest Expenses (Quarter) 2.01M6.36M0.30M20.72M19.50M12.15M0.30M9.43M5.01M8.55M0.50M3.95M0.40M0.50M1.05M2.61M